Condition: Stage I Renal Cell Cancer · Stage II Renal Cell Cancer · Sponsor: Jonsson Comprehensive Cancer Center
This phase I/II trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very tiny glass spheres. These spheres are injected into the artery that feeds the cancer. This process is called radioembolization. Y-90 radioembolization may be a safe and effective treatment for patients with early stage renal cell carcinoma.
This description comes directly from the study's public registry record.
Amelia Ferrer · 310-906-6028 · acferrer@mednet.ucla.edu
Saima Chaabane · (310)794-8995 · schaabane@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| University of Colorado Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06432036